Cargando…
Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?
BACKGROUND: We lack tools to predict treatment and survival outcomes in patients receiving additional BCG therapy as a bladder-preserving therapy in high grade/T1, Tis NMIBC patients who showed persistent/recurrent tumors at three-month follow-up. OBJECTIVES: To assess the predictors of additional B...
Autores principales: | Elsawy, Amr A., Laymon, Mahmoud, Mansour, Islam, Elghareeb, Ahmed, Harraz, Ahmed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373613/ https://www.ncbi.nlm.nih.gov/pubmed/37521452 http://dx.doi.org/10.1080/2090598X.2023.2190687 |
Ejemplares similares
-
Microscopic hematuria and pelvic ultrasonography could rule out flexible cystoscopy during surveillance for T1-low grade non-muscle invasive bladder cancer
por: Awad, Mohamed, et al.
Publicado: (2023) -
Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017) -
BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022) -
The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015) -
Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)